SCHEMBL3778397

SCHEMBL3778397

COC(=O)Cc1ccc(Cl)c2nc(C)c(Sc3ccc(Cl)cc3)c(C)c12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
VDR P11473 1/20 0.40
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.38
TP53 P04637 5/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.37
GAA P10253 2/20 0.36
DHFR P00374 1/20 0.36
TYMS P04818 1/20 0.36
AKR1B1 P15121 1/20 0.35
KDM4E B2RXH2 3/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 1/20 0.35
STAT3 P40763 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788385 0.88 PTGDR2 (0.43) VDRMAPTTP53PTGDR2GAA
SCHEMBL3776832 0.83 VDR (0.41) VDRMAPTTP53PTGDR2KDM4E
SCHEMBL3781729 0.80 ALDH1A1 (0.41) ALDH1A1KDM4EALOX15MAPK1L3MBTL1
SCHEMBL3778746 0.76 TP53 (0.39) MAPTALDH1A1TP53PTGDR2DHFR
SCHEMBL3784962 0.76 PPARD (0.44) VDRMAPTTP53PTGDR2AKR1B1
SCHEMBL3772949 0.73 VDR (0.37) VDRMAPTTP53PTGDR2KDM4E
SCHEMBL3778130 0.70 TLR7 (0.37) ALDH1A1PTGDR2GAAKDM4EHPGD
SCHEMBL3784536 0.69 EGLN1 (0.39) MAPTALDH1A1PTGDR2KDM4ELMNA
SCHEMBL3781373 0.69 TYMS (0.33) VDRMAPTALDH1A1TP53PTGDR2
SCHEMBL14236552 0.68 PLA2G2A (0.40) ALDH1A1KDM4EALOX15MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 VDR 258/4885MAPT 4787/4885ALDH1A1 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.